- Debate over Sam Altman’s claim that AI/robot labor will be “free”: participants argue that robots, computation, and AI IP all have non-zero cost, and even “near-zero marginal cost” is not the same as zero.  
- Discussion of real-world scaling limits: chip-fab robots already show that doubling output still incurs significant additional capital and operational expense.  
- Shared links on horseshoe-crab blood harvesting (sothicbio.science, Popular Mechanics article) as a source of Limulus amebocyte lysate for medical sterility testing.  
- Mention of CRISPR-Cas antimicrobials: 2014 Nature Biotechnology paper on using CRISPR nucleases to create sequence-specific antibiotics (doi:10.1038/nbt.3043).  
- Reference to the 2013 Science paper “Sleep drives metabolite clearance from the adult brain,” highlighting the glymphatic system’s role in neural waste removal.  
- Planning call with BioViva scheduled; channel members compile a “shopping list” of gene-therapy enhancements (ascorbic-acid synthesis, myostatin inhibition, etc.) from diyhpl.us/wiki/genetic-modifications.  
- Price comparison of genome-sequencing vendors: Macrogen claimed to be cheaper than Veritas, with discussion of minimum 100× coverage for reliable data.  
- Nostalgia for early-1990s extropian optimism; critique that the movement produced more speculation than actionable research or engineering.  
- Links to BBC documentaries: “Inside Chernobyl’s Mega Tomb” (robotic cranes dismantling reactor) and “Inside Porton Down: Britain’s Secret Weapons Research Facility.”